Kendall Capital Management Invests $207,000 in Gilead Sciences, Inc. (NASDAQ:GILD)

Kendall Capital Management bought a new position in shares of Gilead Sciences, Inc. (NASDAQ:GILD – Free Report) in the 2nd quarter, according to its most recent 13F filing with the SEC. The fund bought 2,692 shares of the biopharmaceutical company’s stock, valued at approximately $207,000. Several other institutional investors also recently modified their holdings of […]

Related Keywords

United States ,American ,Merdad Parsey ,Andrewd Dickinson ,Complera Eviplera ,Leerink Partnrs ,Piper Sandler ,News Ratings For Gilead Sciences Daily ,Gilead Sciences Stock Performance ,Gilead Sciences ,Wealthplan Investment Management ,Morgan Stanley ,Quarter For Gilead Sciences ,Venturi Wealth Management ,Gilead Sciences Announces Dividend ,Gilead Sciences Profile ,Nasdaq ,Barclays ,Gilead Sciences Inc ,First National Trust Co ,Kendall Capital Management ,Free Report ,Heald Wealth Management ,Plan Investment Management ,Wealth Management ,Get Free Report ,Visit Holdingschannel ,Gilead Sciences Daily ,Nasdaq Gild ,Gild ,Medical ,37555810 ,Sec Filings ,13f ,Hedge Fund Holdings ,Institutional Investor Holdings ,